Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Social Media and Clinical Trial Recruitment
Pharmaceutical Executive
A review of an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Developing Therapies for Treatment Resistant Cancers: Q&A with Russell Hayward
Etira’s CEO discusses recent developments in R&D and with the company’s leadership.
Key Findings of the NIAGARA and HIMALAYA Trials
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Powering Pipelines Forward: Approach Science Differently
Why tapping the value generated for the next set of therapies is critical.
Koselugo Demonstrates Clinically Meaningful Improvement in Adults with Symptomatic, Inoperable Plexiform Neurofibromas
Results from the Phase III KOMET trial found that Koselugo demonstrated a statistically significant objective response rate compared to placebo treating plexiform neurofibromas.
Developing Therapies for Treatment Resistant Cancers: Q&A with Russell Hayward
Etira’s CEO discusses recent developments in R&D and with the company’s leadership.
Key Findings of the NIAGARA and HIMALAYA Trials
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Powering Pipelines Forward: Approach Science Differently
Why tapping the value generated for the next set of therapies is critical.
Koselugo Demonstrates Clinically Meaningful Improvement in Adults with Symptomatic, Inoperable Plexiform Neurofibromas
Results from the Phase III KOMET trial found that Koselugo demonstrated a statistically significant objective response rate compared to placebo treating plexiform neurofibromas.